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Abstract 
Purpose 
To explore how stereoacuity changes during amblyopia treatment.  
Methods 
The Monitored Occlusion Treatment for Amblyopia Study (MOTAS) comprised three 
distinct phases. In the first, baseline, phase two assessments of visual function were made 
to confirm the initial visual and binocular visual deficit. The second phase, refractive 
adaptation, now commonly termed “optical treatment,” was an 18-week period of 
spectacle wear with measurements of logMAR visual acuity and stereoacuity with the 
Frisby test at weeks 0, 6, 12, and 18. In the third phase, occlusion, participants were 
prescribed 6 hours of patching per day.  
Results 
A total of 85 children were enrolled (mean age,  5.1 ± 1.5 years). In 21 children 
amblyopia was associated with anisometropia; in 29, with strabismus; and in 35, with 
both. At study entry, poor stereoacuity was associated with poor visual acuity (P < 0.001) 
in the amblyopic eye and greater angle of strabismus (P < 0.001). Of 66 participants, 
25(38%)  participants who received refractive adaptation and 19 (29%) who received 
occlusion improved by at least one octave in stereoacuity, exceeding test–retest 
variability. Overall, 38 (45%) improved one or more octaves across both treatment 
phases. Unmeasureable stereoacuity was observed in 56 participants (66%) at study entry 
and in 37 (43%) at study exit.  
Conclusions 
Stereoacuity improved for almost half of the study participants. Improvement was 
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observed in both treatment phases. Factors associated with poor or nil stereoacuity at 
study entry and exit were poor visual acuity of the amblyopic eye and large-angle 
strabismus. 
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Amblyopia is the most common cause of visual morbidity in childhood, with a 
prevalence of 1.6% to 3.5%.1 It occurs during the sensitive period for visual 
development2 and is characterized by deficits in spatial vision, including stereovision, 
usually unilateral, and is associated with one or more sensory obstacles, such as 
ametropia, strabismus, or a form vision–depriving condition such as cataract.  
Although many components of spatial vision can be modulated by amblyopia 
therapy, including contrast sensitivity3,4 and positional acuity,5 visual acuity assessed by 
letter optotypes remains the principal means of monitoring change. There is, however, 
little information on how binocular vision changes during amblyopia therapy. This is of 
particular importance because stereopsis is a binocular visual function that is necessarily 
interrupted during occlusion.  
From a functional viewpoint, the condition best suited to promoting normal visual 
development and the attainment of full binocular vision is when the visual input from 
each eye is equal.6 Binocular function emerges around 3 to 4 months of age, along with 
maturation of other components of the visual system, including vergence control and 
cortical development.7 Stereoacuity increases from 800 arcsec at 4 months to 110 arcsec 
by 12 months and approaching near adult levels by 24 months,8 although not attaining 
full adult levels until around 8 to 9 years.9  
Mainstream treatment for unilateral amblyopia has two principal components: 
refractive correction, usually by spectacles, and occlusion by patching or penalization 
(atropine cycloplegia) of the fellow eye. Both interventions individually generate an 
improvement in visual acuity.6 
In this study we examined the changes in stereoacuity that occurred during 
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amblyopia treatment in the Monitored Occlusion Treatment for Amblyopia Study 
(MOTAS). This study was designed to explore the dose–response function of occlusion 
with respect to, primarily, visual acuity, with secondary outcomes including stereoacuity 
and contrast sensitivity. The principal findings of MOTAS have been published 
elsewhere.6,10-12 
Methods 
MOTAS comprised three discrete phases: baseline, refractive adaptation, and occlusion. 
Refractive adaptation is now more commonly referred to as “optical treatment,” but here 
we retain use of the former term for consistency with the original publications.10-12 
Henceforth we refer to refractive adaptation and occlusion as the “treatment phases.” See 
Stewart and colleauges10 for full details of MOTAS methods  
The baseline phase comprised a minimum of two consecutive vision assessments. 
The primary MOTAS outcome measure was logMAR visual acuity. Three letter logMAR 
visual acuity charts were employed: ETDRS, crowded, and single logMAR. The chart 
used depended on the reading ability of the child and was generally age-dependent. To 
ensure consistency, the visual acuity test employed at the first study session was used 
throughout the study period. A secondary visual outcome measure of MOTAS was 
stereoacuity as measured with the Frisby stereotest.13 The Frisby test was chosen as a test 
that all children are able to perform in the age range studied (3-7 years) and also because 
of its fine incremental scale. The test equipment consists of transparent plates, each 
subdivided into four squares with different sized and randomly placed arrowheads printed 
onto one surface and with one square containing a circular target of arrowheads printed 
onto the other surface. The target, which can only be identified in the presence of 
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stereopsis, appears to emerge out of the plate. The Frisby test has three plates of 6 mm, 3 
mm, and 1.5 mm thickness that determine the magnitude of disparity for each test 
distance (20–80 cm), as listed in Table 1. 
The test procedure was as follows. The test cards were presented perpendicular to 
the child’s visual axis at 30 cm. Commencing with the 6 mm plate, if the child correctly 
identified the target on at least twice in three presentations, the thinner plates were then 
presented (avoiding overlapping testing of the same disparity on different plates), and if 
these were also correctly identified the test distance was increased to 40 cm, 50 cm, and 
so on. The test continued with the presentation of progressively finer plates at greater 
distances until the child was unable to identify the target. At this point the tester reverted 
to the previous plate to confirm the end point, the child’s stereoacuity being the finest 
plate correctly identified at the farthest test distance. If the child failed the thickest plate 
at 30 cm, then the thickest plate was presented at 20 cm. Children who could not resolve 
the thickest plate at 20 cm were recorded as having nil stereoacuity. 
Ocular alignment was assessed using the cover-uncover test to observe the 
presence of heterotropia and the alternate cover test to observe any increase in angle on 
dissociation or presence of heterophoria and recovery upon removing the cover. The 
angle of deviation was measured by the prism and alternate cover test at near (1/3 m) and 
distance (6 m). 
Refractive error was assessed by one author (ARF) using cycloplegic 
retinosocopy. Significant refractive error was considered to be 1.50 D bilateral 
hypermetropia;  1.50 D bilateral myopia; 0.75 D bilateral astigmatism and  1.00 D 
anisometropia.  
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Children who required spectacle correction entered the refractive adaptation 
phase, whereas those not requiring spectacle correction entered the occlusion phase. All 
children with significant refractive error were instructed to wear spectacles full-time and 
were scheduled to return for four vision assessments at 6-week intervals from week 0 
(onset of spectacle wear) until 18 weeks of refractive adaptation was completed—a 
period that our previous research indicated would allow for all significant improvement 
attributable to spectacle wear to have occurred.14 Children remaining eligible for 
occlusion (see below for inclusion criteria) entered the occlusion phase and were 
prescribed 6 hours occlusion per day (a dose considered moderate, allowing for under- 
and over-concordance). Occlusion episodes received were recorded to the nearest minute 
by an occlusion dose monitor.15 Both visual function and the monitored occlusion dose 
were recorded at 2-week intervals until visual acuity ceased to improve (two inflexions 
on a visual acuity versus time plot or change not exceeding ± 0.02 log units difference on 
three consecutive visits). This sensitive measure was used to ensure that treatment was 
not stopped before all reasonable gains had occurred (see Stewart and collegues10). On 
completion of the occlusion phase, participants left the study and were returned to 
standard clinical care. No patient had any other ophthalmic intervention, including 
surgery, during the study period.  
Inclusion eligibility criteria were age 3 to 8 years, anisometropia and/or 
strabismus, an interocular acuity difference of at least 0.1 logMAR, written parental 
consent, no previous occlusion, and the absence of either ocular pathology or learning 
difficulties. The study was administered according to the Helsinki Declaration II and 
approved by Hillingdon and St Mary’s Hospital, London, NHS Trusts’ Local Research 
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Ethics Committees. 
 Statistical Analysis 
The cohort for our analyses consisted of participants who had a stereoacuity measurement 
at both the start and end of one or both treatment phases. Using multivariate linear 
regression models, we investigated what factors are associated with stereoacuity, 
conducting two main analyses: an analysis of associations with baseline stereoacuity, and 
an analysis of associations with stereoacuity at the end of (each phase of) treatment. The 
following covariates were considered: age, visual acuity in the amblyopic eye, the 
presence of anisometropia, and the angle of any strabismus (the last two being measured 
only at study entry). In addition, models of stereoacuity at end of treatment phase 
controlled for stereoacuity at the start of that particular treatment phase. Two-way 
interaction terms were considered, and backward selection based on the Akaike 
Information Criterion was used for final model selection.16 Time in treatment was not 
included in the models of outcome stereoacuity. 
Due to evidence of nonlinear relationships with stereoacuity at study entry and 
end of treatment, age and the amount of anisometropia were categorized. Age was 
divided into three categories: <48 months, ≥48 to <72 months, and ≥72 months.6 
Amblyopia type was classified as with anisometropia (≥ 1 D) and with only strabismus; 
therefore, our new anisometropia group consisted of those with mixed amblyopia as well 
as those with purely anisometropic amblyopia. Although this seemingly provides less 
information than the trichotomy of anisometropia/mixed/strabismus used to identify 
patient characteristics, we considered it important to include angle of strabismus, which 
was categorized into three levels: slight (<10°), moderate (≥10° and <25°), and 
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large (≥25°). 
The lowest possible measure of stereoacuity was 1,200 arcsec and participants not 
attaining this level were recorded as having ‘nil’ stereoacuity which were assigned the 
next octave value of 2,400 arcsec in the analysis.17 Sensitivity to this procedure was 
investigated by performing analyses with extreme values for nil stereoacuity of 1,500 and 
10,000 arcsec. All analyses were performed with stereoacuity log-transformed (to base 
10) and were implemented in the statistical software package R. Mann-Whitney-
Wilcoxon tests were used to identify whether changes in stereoacuity were significant in 
and between study phases. 
Results 
Primary Analysis 
A total of 85 children were included (mean age, 5.1 ± 1.5 years). In 21 children (mean 
age, 5.6 ± 1.2  years), amblyopia was associated with anisometropia; in 29 (mean age, 4.7 
± 1.2 years), with strabismus; and in 35 (mean age, 5.3 ± 1.5 years), with both 
anisometropia and strabismus (mixed). Of the 85, 50 completed both treatment phases, 16 
received refractive adaptation, and 19 received occlusion only (8 had no refractive error 
and 11 had undergone full refractive adaptation prior to study entry). The characteristics 
of individuals at study entry are summarized in Table 2, where we consider first the entire 
cohort and second those with measurable stereoacuity at study entry. Of the 85 
participants, 56 (66%) had nil stereoacuity at study entry. Details of strabismus 
classification are shown in Table 3. Further details of baseline characteristics of 
participants have been published elsewhere.11 Mean concordance with the prescribed 
occlusion dose rate (6 hours/day) was 2.8 hours (48%). Only 10 (14%) of participants 
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achieved an average concordance within 30 minutes of the prescribed dose rate. 
Figure 1A summarizes stereoacuity at start and end of each treatment phase; 
Figure 1B represents the progress of those with measureable stereopsis at the start and 
end of each phase to enable visualization of progression through the study.  
Refractive Adaptation Phase 
In the 66 children who entered the refractive adaptation phase, the median (IQR) visual 
acuity for amblyopic eyes improved from 0.56 ± 0.41 to 0.34 ± 0.54 logMAR, a mean 
improvement of 0.22 ± 0.18; (range, 0.0 to 0.6). Following refractive adaptation, 13 study 
participants (16.7%) no longer had amblyopia according to the study definition.  
The median (IQR) change in stereoacuity during refractive adaptation was as 
follows: for all children (n = 66), 3.38 ± 0.60 to 2.78 ± 1.31 (P = 0.006); for the 21 
children with stereoacuity at the outset, 2.23 ± 0.74 to 2.04 ± 0.49 (P = 0.01); for the 14 
children who gained stereoacuity during this phase (n = 14), 2.78 ± 0.49 arcsec. (These 
values equate to 2,400 to 600 and 170 to 110 and 600 log arcsec, respectively.) Thirty-
one continued to have nil stereoacuity. 
Occlusion 
During the occlusion phase (n = 69) median (IQR) visual acuity for amblyopic eyes 
improved from 0.48 ± 0.49 to 0.15 ± 0.35 logMAR: a mean improvement of 0.33 ± 0.18 
(range, 0.0-1.2]. Analyzing the change in stereoacuity during the occlusion phase was as 
follows: for all children (n = 69), 3.38 [1.15] to 2.78[1.51] (P = 0.21); those with 
stereoacuity at the start of the phase (n = 32), 2.18 [0.60] to 1.88 [0.49] (P = 0.01); those 
that gained stereoacuity in this phase (n = 6), achieved 2.78 [0.23] log arcsec. (These 
values equate to 2,400 to 600 and 170 to 75 and 2,400 to 600 log arcsec, respectively.) 
 11 
Thirty-one continued to have nil stereoacuity. 
Change in Stereoacuity 
Figure 2 summarizes the change in stereoacuity during each treatment phase in terms of 
octave steps (improvement of 1 octave equivalent to a decrease in 0.3 log arcsec or 
simply a halving of stereoacuity on its original, arcsec scale). Improvement by at least 
one octave, the amount required to exceed test–retest variability,17 was achieved by 25 
children (38%) who received refractive adaptation, 19 (28%) who received occlusion, and 
38 (45%) who underwent refractive adaptation and/or occlusion. Only 6 children (15%) 
improved by at least 1 octave in each phase of treatment. One participant in the refractive 
adaptation phase and 2 participants in the occlusion phases demonstrated a deterioration 
of stereopsis by 1 octave. Seven participants with measureable stereopsis demonstrated 
improvements <1 octave in each phase and overall. Thirty-seven (44%) had nil 
stereoacuity throughout the study. Table 4 summarizes characteristics of participants at 
study exit. 
Regression Analysis 
For the purposes of fitting multivariate normal linear regression models, age at study 
entry was categorized into the three groups: <48 months (n = 27), ≥48 and <72 months (n 
= 33), and ≥72 months (n = 35). Those with anisometropic and mixed amblyopia were 
grouped into a single anisometropia group (to be compared with those with purely 
strabismic amblyopia). Absolute angle of strabismus was categorized into three groups: 
slight (<10°, n = 48), moderate (≥10° to <25°, n = 19), and large (≥25°, n = 18). Results 
of the model for stereoacuity at study entry are summarized in Table 5. All two-way 
interaction terms were eliminated during the model selection procedure, as was 
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anisometropia, which was not found to contribute significantly to the model (P = 0.176). 
At study entry, controlling for age (P > 0.25 for both categories), poor 
stereoacuity was associated with poor visual acuity in the amblyopic eye, with a 1 
logMAR decline of visual acuity on average corresponding to a decline in stereoacuity of 
0.51 log arcsec. Relative to those with mild strabismus, poor stereoacuity was not 
significantly associated with moderate strabismus (P = 0.083) but was with severe 
strabismus (P = 0.007). After controlling for the other variables, those with severe 
strabismus had, on average, 0.38 log arcsec worse stereoacuity than those with mild 
strabismus. A separate analysis did not find a significant difference in stereoacuity 
between those with moderate and severe strabismus (P = 0.341). Analyses carried out 
with values of 1,500 and 10,000 for nil stereoacuity returned similar results. 
Outcome stereoacuity was modeled across the entire cohort of 85 individuals, 
with those 50 who received both treatments contributing to the model twice (once as 
refraction and once as occlusion patients). As with our multivariate linear model of 
stereoacuity at study entry, all two-way interaction terms were eliminated during model 
selection, as was anisometropia (P = 0.696). The results of fitting our final model are 
summarized in Table 6. After controlling for stereoacuity at start of treatment (P < 0.001) 
and age (P = 0.264 and P  < 0.001 for the 48-72 and >72 age categories, respectively), 
worse stereoacuity was again associated with worse visual acuity in the amblyopic eye at 
start of treatment (P < 0.001), with a 1 logMAR worsening of visual acuity on average 
corresponding to a worsening in stereoacuity of 0.30 log arcsec. Relative to those with 
mild strabismus, those with moderate (P = 0.01) and severe (P < 0.001) strabismus were 
found to have poor stereoacuity (0.20 and 0.33 log arcsec, respectively). Again, there was 
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no significant difference in stereoacuity between those with moderate and severe 
strabismus (P = 0.138). 
A mixed effects model approach that accounted for the repeated-measure aspect 
of the dataset (with most participants contributing two sets of covariate and outcome 
measurements) returned similar results, as did analyses with extreme values of 1,500 and 
10,000 for nil stereoacuity. 
Discussion 
This study(MOTAS) examined factors influencing changes in stereopsis during 
amblyopia treatment. The study participants represent a typical population of children 
with amblyopia undergoing treatment. We found that severe amblyopia and a greater 
angle of strabismus were associated with reduced or absent stereoacuity. Stereoacuity can 
improve in either the refractive adaptation and occlusion phases of treatment; however, 
most individuals improve during one or the other. 
At study entry, patients with anisometropia were more likely to have better 
stereopsis than those with strabismus. This finding is consistent with Loudon and 
colleagues,18 who showed those children with strabismus detected by screening had a 
lower binocularity score compared to those with anisometropia. However, by study exit 
this was not the case in our cohort, indicating that initial visual acuity and the angle of 
strabismus were the most important factors associated with improvement in stereoacuity. 
Optical treatment of amblyopia is now well documented to improve visual acuity 
for all types of amblyopia.19-21 The present study demonstrates that stereoacuity not only 
improves during this phase of treatment for individuals with anisometropia, reported 
recently by Richardson and colleagues, 22 but also that individuals with all three types of 
 14 
amblyopia demonstrate significant improvements in stereoacuity.  
Documentation of stereoacuity improvement during each treatment phase is 
sparse, mainly because until recently optical treatment and occlusion were not fully 
differentiated. In MOTAS, for some individuals stereoacuity improved during the 
occlusion phase. The data suggest that improvement in stereoacuity was more likely in 
the refractive adaptation phase rather than the occlusion phase; however, the data was 
biased by those that improved sufficiently in this first phase to make continued treatment 
unnecessary, and further studies, with larger numbers of patients, are required. By 
definition, occlusion precludes form vision of the fellow eye and thus disrupts any 
potential binocular vision. It therefore might be speculated that for those participants with 
amblyopia and with measureable stereopsis, occlusion treatment could cause a 
deterioration of this aspect of spatial vision. Yet experimental work has shown that short 
daily periods of binocular vision, if concordant and continuous, outweigh or protect 
against much longer daily periods of monocular deprivation (allowing the development of 
normal visual acuity in both eyes of kittens).23 On this basis, for the human condition, 
providing that occlusion is not full-time (ie, all waking hours) it is likely that some period 
of monocular viewing can be tolerated without negatively affecting the potential for 
improved binocular function. It could be instructive to observe changes in stereoacuity 
after occlusion is discontinued; unfortunately, the study design did not permit continued 
observation. We postulate that stereoacuity might continue to improve following 
acquisition of better visual acuity in the occlusion phase and discontinuation of treatment 
that could disrupt or prevent improvement of stereoacuity. 
Superior stereoacuity was associated with superior visual acuity at the start and 
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end of each treatment phase. Superior visual acuity and reduction in the difference 
between the visual inputs of each eye are likely to allow for better discrimination of 
stereoacuity images—a finding reported for those with anisometropic amblyopia by 
Wallace and colleagues,24 who also found a relationship between better stereoacuity and 
less anisometropia at baseline. Induced anisometropia of as little as 1.0 D has been 
reported to degrade stereopsis.25 Due to the small numbers in our study cohort, we were 
unable to explore the relationship between amount of anisometropia and stereoacuity. 
We observed a correlation between logMAR visual acuity and log stereoacuity. 
This has also been documented by Lee and Isenberg,26 who reported a significant linear 
relationship between stereoacuity improvement with occlusion and visual acuity 
improvement, irrespective of presence of small-angle or intermittent strabismus. 
 When visual acuity is degraded with the use of fogging plus lenses, stereoacuity is 
reported to decrease approximately proportionally to the reduction of visual acuity.27 This 
raises the questions, What level of interocular difference is consistent with good 
stereopsis? How much difference causes degradation of stereopsis? Odell25 report that 
visual acuity deficits degrade stereoacuity more severely when using random dot rather 
than with real depth (Frisby, FD2) tests. Odell and colleagues25 reported good stereopsis 
on the Frisby test until visual acuity degrades to 20/100 (0.70 logMAR equivalent), with 
most subjects maintaining gross stereoacuity at 20/320 (1.2 logMAR equivalent). In 
MOTAS, those without stereoacuity at study exit had a median [IQR] consistent with 
these values (0.70 [0.51] logMAR).  
Visual acuity of the amblyopic eye and angle of strabismus are strong predictors 
of improvement in stereoacuity during treatment. Individuals with angles of strabismus 
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>25 D are unlikely to achieve stereoacuity. This will consolidate the belief that early 
surgery to reduce the angle of strabismus is beneficial provided patients have good visual 
acuity and achieve successful alignment.9,28,29 Analysis of angle of strabismus and 
stereoacuity was limited to three groups (<10 D, 10 D to <25 D and >25 D) in the present 
study, but did not distinguish between manifest and latent strabismus due to the small 
sample size. Therefore within the <10 D and 10 to <25 groups there were some 
individuals that had no mainifest deviation. Further modeling of the effect of angle of 
strabismus on stereoacuity and improvement during treatment warrants discrimination 
between latent and manifest deviations as well as angle size. Furthermore, recovery of 
fusion30,31,29 and stereopsis has been observed even in those who had strabismus onset 
before visual maturity (<9 years). The visual outcomes of patients with infantile esotropia 
have been reported to be substantially improved if the misalignment is corrected 
surgically, early in life.9,32-34 Drover and colleagues9 also suggest that early muscle 
surgery could be associated with greater prevalence of stereopsis and be beneficial to 
subsequent motor development.  
In conclusion, stereoacuity improved for almost half of the study participants, 
even for a proportion of those without stereopsis at the outset. Improvement can occur 
during both refractive adaptation and occlusion. Children in whom stereoacuity did not 
improve had significantly poorer visual acuity at the start and end of treatment and a 
larger angle of strabismus. 
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Table 1. Disparities in arcsec for each Frisby test plate, as a function of test distance.  
Table 2. Characteristics of MOTAS participants at study entry. With the exception of 
amblyopia type, entries are of the form “median (interquartile range).” Note, the angle of 
strabismus in measured with alternate prism cover test. 
Table 3. Ocular alignment at baseline. Range = angle of deviation at near and distance 
fixation, with and without refractive correction. PCT = Prism Cover Test (using alternate 
prism cover testing); BO = Base Out; BI = Base In. N.B. The corrected column includes 
measurements from children with insignificant refractive error (defined previously in the 
Method).10 
Table 4. Characteristics of MOTAS study participants at study exit. With the exception of 
amblyopia type, entries are of the form “median (interquartile range)”. Note that 3.38 log 
stereoacuity is an arbitrary assignment for those with nil stereoacuity. 
Table 5. Multivariate linear regression model of (log transformed) stereoacuity at study 
entry. Age categories are relative to those under 48 months, anisometropia compares 
those classified as having anisometropia to those with purely strabismic amblyopia (n = 
85). Regression coefficients translate to the increase in stereoacuity at study exit for 
either a one unit increase in the corresponding variable or, for categorical variables, 
relative to its baseline. 
Table  6. Multivariate linear regression model of (log transformed) stereoacuity at end of 
treatment phases. Age categories are relative to those under 48 months, anisometropia 
compares those classified as having anisometropia to those with purely strabismic 
amblyopia, phase compares occlusion phase with refraction phase. Stereoacuity, age and 
visual acuity measured at start of treatment phase, all other measurements taken at study 
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entry (n = 85). Regression coefficients translate to the increase in stereoacuity at study 
exit for either a one unit increase in the corresponding variable or, for categorical 
variables, relative to its baseline. 
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Legends 
FIG 1. A, Stereoacuity at start and end of refraction (n = 66) and occlusion (n = 69) 
treatment phases. Note that participants with unmeasurable stereoacuity were assigned 
2400 arcsec (3.38 log arcsec). Stereoacuity is poor at the start of the occlusion phase 
compared to the end of the refractive adaptation due to some patients leaving the study at 
this point (n = 16) and  others (n = 19) starting the study at the beginning of the occlusion 
phase. B, Stereoacuity at start and end of refraction (n = 21) and occlusion (n = 32) 
treatment phases, excluding those with unmeasurable stereoacuity at the start of each 
treatment phase. Boxes indicate 25% and 75% quartiles; whiskers extend to the most 
extreme point not more than 1.5 times the interquartile range from the median. 
FIG 2. Change (improvement) in stereoacuity during treatment phases and treatment as a 
whole. An improvement of 1 octave corresponds to a halving of stereoacuity on its 
original, arcsec, scale, or a decrease of 0.3 log arcsec. 
